ClinicalTrials.gg
CompletedNCT02146534Updated Mar 6, 2019

Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients

A Phase 4 interventional study of extended release fampridine and Placebo in Multiple Sclerosis, sponsored by Clinique Neuro-Outaouais. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-06.

Sponsored by Clinique Neuro-Outaouais · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing 4-Aminopyridine in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. 4-Aminopyridine · Multiple Sclerosis.

Enrollment
19th of 27
44 · median 64
Started
2013
with 1 other
Phase 4
8 of 27
none open now
Registered
16th of 27
by date
Lead sponsor
1 of 27
Clinique Neuro-Outaouais

Among the 27 studies testing 4-Aminopyridine in Multiple Sclerosis, this one is the 19th largest by enrollment, is one of 2 that started in 2013, is one of 8 in phase 4, and was the 16th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 27 studies testing 4-Aminopyridine in Multiple Sclerosis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4-Aminopyridine

4-Aminopyridine: first FDA approval 2010 (AMPYRA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing 4-Aminopyridine in Multiple Sclerosis, or all of them as a file.
02

Study summary

Phase 4, single center, double-blind, placebo-controlled study. Fifty (50) patients with MacDonald criteria (2005) multiple sclerosis will undergo active motor training as per the NeuroGym protocol, consisting of 3 sessions of 1 hour per week for a period of 6 weeks (total of 18 sessions).

Half of the patients will be randomized to receive prolonged-release fampridine 10 mg BID as per label, and the other half will receive a placebo BID.

All patients will continue to take their medication (fampridine or placebo) during a subsequent observational period of 8 weeks. Patients will be evaluated at times -4, 0, 6 and 14 weeks.

Study Objectives:

Primary: To demonstrate that MS subjects treated with prolonged-release fampridine 10mg BID will show greater benefit from active motor training as compared with subjects treated with placebo in terms of incidence of responders, degree of response, and duration of response.

Secondary: To demonstrate that MS subjects treated with prolonged-release fampridine 10mg BID will show greater benefit from active motor training as compared with subjects treated with placebo in terms of quality of life measures.

Read the detailed description

Rationale for the study

Prolonged-release fampridine (4-aminopyridine) is a voltage-gated potassium channel blocking agent. It relieves conduction block in demyelinated nerve fibers by blocking voltage-gated potassium channels on the paranodal axon membranes in vitro. It enhances synaptic transmission by blocking repolarizing potassium currents thus increasing the size of the presynaptic action potential and thus increasing transmitter release. It has been shown in multiple sclerosis patients to improve walking capabilities as measured by the timed 25 feet walk test by more than 20% in approximately 34% of subjects. Prolonged-release fampridine also has measurable effects on motor evoked potentials with transcranial magnetic stimulation in patients with multiple sclerosis and partial spinal cord injuries.

The brain is a dynamic plastic organ that continuously adapts to the demands made upon it. Prolonged-release fampridine by improving nerve conduction in multiple sclerosis patients has the potential to enhance brain plasticity. Activities or processes that call upon such plasticity could therefore also benefit from prolonged-release fampridine. Active motor training when combined with prolonged-release fampridine in patients with multiple sclerosis could therefore show a larger and more sustained measurable clinical benefit than with active motor training alone.

Prolonged-release fampridine by enhancing brain plasticity through improved nerve conduction in the central nervous system can potentiate the clinical benefits of active motor training as measured via assessments of walking capabilities and quality of life in subjects with multiple sclerosis of varying severity.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of McDonald criteria MS of all types and of age 18 and older.
  • Subjects who meet the prescribing criteria for Fampyra as per product monograph.
  • Therapeutic stability (MS and symptomatic treatment) for 3 months prior to screening and for the duration of the study.
  • Pyramidal system functional assessment score of 2 or greater and the ability to complete all the assessments with or without aids.
  • Female subjects of must practice effective during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Any to receiving fampridine as per product monograph including but not limited to prior history of epilepsy, renal dysfunction (abnormal serum creatinine), concomitant treatment with cimetidine or quinidine.
  • Ongoing treatment with fampridine or prior history of fampridine intolerance or ineffectiveness
  • Any other condition that would preclude them from undergoing the NeuroGym training.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    fampridine

    extended release fampridine 10mg BID PO for 14 weeks

    Drug: extended release fampridine

  • Placebo comparator
    placebo

    placebo pill BID PO for 14 weeks

    Drug: Placebo

Interventions

  • Drug4-AminopyridineStudies of 4-Aminopyridine4-Aminopyridine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    pts will receive Fampyra 10 mg BID PO for the duration of the study

    Also known as: Fampyra

  • DrugPlacebo

    placebo will be taken PO BID

06

What researchers measure

Primary outcomes

  1. change in mobility

    timed 8 minutes walk (T8MW) 6 minutes walk (6MW) five times sit to stand test (FTSST)

    Time frame: over 6 and 14 weeks

Secondary outcomes

  1. change in quality of life

    multiple sclerosis impact scale (MSIS-29) short form health survey (SF-36)

    Time frame: over 6 and 14 weeks

07

Study locations

1 site
  • Clinique Neuro-Outaouais
    Gatineau, Quebec J9J 0A5, Canada
08

References and documents

Publications

  • Jacques F, Schembri A, Nativ A, Paquette C, Kalinowski P. Prolonged-Release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: A Pilot, Double-Blind, Randomized, Placebo-Controlled Study. Mult Scler J Exp Transl Clin. 2018 Mar 9;4(1):2055217318761168. doi: 10.1177/2055217318761168. eCollection 2018 Jan-Mar. PubMed 29552356 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2014
First posted
May 26, 2014
Start
Dec 2013
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Last update
Mar 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02146534
Lead sponsor
Clinique Neuro-Outaouais
Collaborators
CogState Ltd.
Responsible party
Sponsor
First posted
May 26, 2014
Start date
Dec 2013
Primary completion
Jan 2016
Completion
Jan 2016
Last update
Mar 6, 2019

Study contacts

Francois H Jacques, MD FRCP
principal investigator · Clinique Neuro-Outaouais

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4-Aminopyridine

Start the discussion